Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti Her2 Therapy.”

141 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 141 results

Large-scale testing (Phase 3)Looking for participantsNCT06989112
What this trial is testing

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Who this might be right for
Endometrial Cancer
AstraZeneca 600
Testing effectiveness (Phase 2)Ended earlyNCT04467515
What this trial is testing

Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Who this might be right for
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
Precirix 13
Not applicableEnded earlyNCT02580045
What this trial is testing

Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer

Who this might be right for
Metastatic Cancer Patients on an Anti-cancer TherapyAdvanced CancerBrain Metastasis
Duke University 3
Not applicableUnknownNCT04769050
What this trial is testing

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Who this might be right for
Breast Cancer
Fudan University 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 320
Testing effectiveness (Phase 2)Looking for participantsNCT07007559
What this trial is testing

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer, Metastatic
ALX Oncology Inc. 120
Not applicableLooking for participantsNCT07527741
What this trial is testing

Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Who this might be right for
Early-stage HER2+ Breast Cancer
Hoffmann-La Roche 100
Early research (Phase 1)Looking for participantsNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Not applicableUnknownNCT06481553
What this trial is testing

RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody

Who this might be right for
Breast Cancer Stage IV
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 480
Early research (Phase 1)Temporarily pausedNCT03970382
What this trial is testing

Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Who this might be right for
Solid Tumor
PACT Pharma, Inc. 21
Testing effectiveness (Phase 2)Study completedNCT02983045
What this trial is testing

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Who this might be right for
MelanomaRenal Cell CarcinomaNon Small Cell Lung Cancer+4 more
Nektar Therapeutics 557
Early research (Phase 1)Ended earlyNCT03661424
What this trial is testing

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

Who this might be right for
Breast Cancer FemaleLeptomeningeal Metastases
University of Virginia 3
Testing effectiveness (Phase 2)Looking for participantsNCT07471776
What this trial is testing

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)
Fudan University 45
Early research (Phase 1)Active Not RecruitingNCT04052555
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Looking for participantsNCT06508216
What this trial is testing

Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 50
Testing effectiveness (Phase 2)Ended earlyNCT03430466
What this trial is testing

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 1
Early research (Phase 1)Study completedNCT02390427
What this trial is testing

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerRecurrent Breast Cancer
Otto Metzger, MD 68
Testing effectiveness (Phase 2)Looking for participantsNCT05834764
What this trial is testing

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 188
Testing effectiveness (Phase 2)Ended earlyNCT00522457
What this trial is testing

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Neovii Biotech 19
Testing effectiveness (Phase 2)Ended earlyNCT05744375
What this trial is testing

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
Spanish Breast Cancer Research Group 2
Load More Results